Recurring revenue for the full year exceeded $46.3 million, marking a 15% increase over 2024. The company placed 15 ALLY Robotic Cataract Laser Systems in Q4 2025, bringing the total installed base to approximately 200 systems, a 48% increase from the end of 2024. As of December 31, 2025, LENSAR had a backlog of 13 ALLY Systems pending installation. The total combined installed base of LENSAR Laser Systems and ALLY Systems increased to approximately 435 systems, representing a 13% growth compared to the previous year.
Despite the challenges faced, including acquisition-related costs from a terminated merger with Alcon Research, LENSAR's management expressed confidence in the company's operational execution and strategic outlook. The net loss for Q4 2025 was reported at $1.5 million, significantly reduced from a net loss of $18.7 million in Q4 2024. This improvement was largely due to changes in the fair value of warrant liabilities associated with stock fluctuations. The company also highlighted that 79% of its revenue for both the fourth quarter and the full year came from recurring sources, underscoring the strength of its business model.
LENSAR's management will host a conference call and live webcast to discuss these results and provide updates on the company's strategy moving forward. The call is scheduled for March 31, 2026, at 8:30 a.m. ET, and will be accessible via the company's investor relations website.
